Volitionrx (VNRX) Convertible Debt (2025 - 2026)

Volitionrx's (VNRX) quarterly Convertible Debt came in at $1.4 million in Q4 2025, down 36.32% on a QoQ basis from $2.3 million in Q3 2025.

Volitionrx (VNRX) Convertible Debt (2025 - 2026) Analysis & Trends

Volitionrx (VNRX) has 1 years of Convertible Debt data on file, last reported at $1.4 million in Q4 2025.

Quarterly Convertible Debt changed N/A year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (changed N/A YoY) and the FY2025 annual result came in at $1.4 million, changed N/A from the prior year.
Convertible Debt fell to $1.4 million in Q4 2025, from $2.3 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $2.9 million in Q2 2025 to a low of $1.4 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.24 Bn	193.64 Bn	7.27 Bn
2	Stryker	128.63 Bn	125.15 Bn	4.50 Bn
3	Medtronic	119.19 Bn	109.97 Bn	6.41 Bn
4	Boston Scientific	73.51 Bn	72.97 Bn	3.85 Bn
5	Edwards Lifesciences	52.11 Bn	47.85 Bn	1.35 Bn
6	Dexcom	34.64 Bn	32.70 Bn	830.00 Mn
7	GE HealthCare Technologies	34.01 Bn	31.90 Bn	2.18 Bn
8	Koninklijke Philips	26.40 Bn	23.08 Bn	4.55 Bn
9	Steris	23.14 Bn	22.65 Bn	684.20 Mn
10	Volitionrx	1.20 Mn	-1.60 Mn	-

Download Data